ANTI-CAM-CYSTEINE CLONE 4E7 ZOOMAB RABBIT MONOCLONAL (C15-1669-296)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 4E7 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects Carbamidomethyl-cysteine (CAM-Cysteine) modified proteins.

Immunogen

A linear peptide corresponding to 26 amino acids from the C-terminal region of human Myeloid associated differentiation marker like 2 ( MYADML2 ) with CAM modification at two Cysteine residues.

Application

Quality Control Testing

Evaluated by Western Blotting in lysate from HEK293 cells treated with Iodoacetamide.

Western Blotting Analysis (WB): A 1:10,000 dilution of this antibody detected CAM-cysteine modified proteins in lysate from HEK293 cells treated with Iodoacetamide (1 mM for 10 min), but not in untreated cells.

Tested applications

Enzyme Immunoassay Analysis (ELISA): A series of dilution from a representative lot detected CAM-cysteine modified proteins in HEK293 cells treated treated with Iodoacetamide (IAM).

Flow Cytometry Analysis: 0.1 μg from a representative lo detected CAM-cysteine modified proteins in HEK293 cells treated with Iodoacetamide (IAM).

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected CAM-cysteine modified proteins in HEK293 cells treated with Iodoacetamide (IAM).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Evaluated by Western Blotting in lysate from HEK293 cells treated with Iodoacetamide.

Western Blotting Analysis (WB): A 1:10,000 dilution of this antibody detected CAM-cysteine modified proteins in lysate from HEK293 cells treated with Iodoacetamide (1 mM for 10 min), but not in untreated cells.

Target description

Post-translation regulation of cysteine sulfhydryl groups can affect molecular function of proteins. In several secreted proteins, cysteine thiols undergo oxidation to form intramolecular disulfide bonds, which play key roles in protein secondary structure and function. In order to be quantified in a protein cysteine residue requires modification. Thiol group of cysteine can be blocked by a variety of reagents, including iodoacetic acid and iodoacetamide. Iodoacetate treatment can produce S-carboxymethyl derivative of cysteine, but it introduces a new negative charge into protein. However, when such charge difference is undesirable, iodoacetamide is used to derivatize cysteine to produce carboxamidomethyl cysteine, an irreversible covalent product. These modifications in proteins can serve as markers for cysteine-AGE formation and can be used as marker for mitochondrial damage during aging. Antibodies that react with carbamidomethyl-cysteine (CAM-cys) can provide multiple protein bands when subjected to Western blotting of lysates treated with iodoacetamide. This ZooMAbZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Cartee, NMP., and Wang, MM. (2020). PLoS ONE 15(9); e0239464; Cartee, NMP., et al. (2020). PLoS One. 15(11); e0242376).

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

Reconstitution

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.